Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.

Condition:   TIA
Intervention:   Other: Non-Interventional Study
Sponsors:   Andrew Penn;   Genome Canada;   Genome British Columbia;   Genome Alberta;   Heart and Stroke Foundation of Canada;   Stroke Services BC;   Bruker Daltonics;   LifeLabs
Completed - verified February 2017

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

Conditions:   Dementia;   Cognition Disorders;   Cerebral Ischemic Events
Interventions:   Drug: Dabigatran Etexilate;   Drug: Warfarin
Sponsors:   Intermountain Health Care, Inc.;   Boehringer Ingelheim
Not yet recruiting - verified January 2017

Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation

Conditions:   Coronary Artery Disease;   Aortic Valve Stenosis;   TAVI;   PCI
Intervention:   Procedure: PCI
Sponsors:   Rigshospitalet, Denmark;   Aarhus University Hospital;   Aalborg Universitetshospital;   Odense University Hospital;   Lund University Hospital;   Karolinska University Hospital;   Rikshospitalet University Hospital;   Haukeland University Hospital;   Helsinki University Central Hospital;   Tampere University Hospital;   Oulu University Hospital
Not yet recruiting - verified February 2017

Reproducibility Study of Transcranial Doppler

Condition:   Stroke
Intervention:   Diagnostic Test: Transcranial Doppler Ultrasound
Sponsor:   University of Edinburgh
Not yet recruiting - verified February 2017

Analysis of the Impact of the Fragility of the Over 70 Years of TIAprognosis

Conditions:   Vascular;   Stoke;   Ischemic;   Transient Ischemic Attack
Intervention:   Other: No intervention
Sponsor:   Groupe Hospitalier Paris Saint Joseph
Recruiting - verified July 2016

Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon

Condition:   Hyperglycemia
Intervention:   Device: percutaneous coronary intervention
Sponsor:   Second University of Naples
Completed - verified February 2017

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study

Condition:   Congestive Heart Failure
Intervention:   Other: Monitoring on heart failure therapy
Sponsors:   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified February 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified February 2017

Program for the Identification of "Actionable" Atrial Fibrillation in the Family Practice Setting

Condition:   Atrial Fibrillation
Interventions:   Other: 30 Second Pulse Check;   Device: Watch BP Home A;   Device: HeartCheck Hand-held ECG device
Sponsors:   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR)
Completed - verified February 2017

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Completed - verified February 2017